Variable Mean (SD)* n(%) P-value**
  Number of blood transfusions before TxR§ 0.80 (0.66) - -
Average time between TxR and VL (months) 21.3 (16.15) - -
Acute rejection episode 0.93 (0.74) - -
Blood transfusion before TxR
Yes   13(43.3) 0.465
No   17(56.7)
Blood type of recipient
Serotype O   14(46.7) 0.025
Serotype A   13(43.3)
Serotype B   3 (10.0)
Rh factor of recipient
Positive   22(73.3) 0.011
Negative          8(26.7)
Incompatible mismatches, recipient–donor
≤ 3 mismatches   25(83.3) 0.001
> 3 mismatches   5 (16.7)
Use of prednisone
Yes   30 (100.0) -
No   0(0.0)
Use of azathioprine
Yes   6 (20.0) 0.001
No   22(80.0)
Use of cyclosporine
Yes   11(36.7) 0.200
No   19(63.3)
Use of tacrolimus
Yes   17(56.7) 0.565
No   13(43.3)
Use of MMF
Yes   27(90.0) 0.000
No   3(10.0)
Induction with monoclonal antibody
Yes   21(70.0) 0.043
No   9 (30.0)
Acute rejection post-transplantation
Yes   12(40.0) 0.362
No   18(60.0)
Patients with VL before TxR  
Yes   0. (0.0) -
No   30 (100.0)
CMV infection post-transplantation
Yes   12(40.0) 0.362
No   18(60.0)
Bacterial infection post-transplantation
Yes   11(36.6) 0.002
No   19(73.4)
Recipient with positive serology for other viruses  
No   20(66.7) 0.068
Yes   10(27.0)
TxR§: renal transplantation; VL: visceral leishmaniasis; Rh: Rhesus factor; MMF, Mycophenolate mofetil; CMV: cytomegalovirus. **χ2 test. Mean (SD)*, Mean (SD), Mean (Standard Deviation); Categorial variables are reported as n (%)
Table 3: Clinical characteristics of 30 renal transplant recipients with posttransplantation Visceral Leishmaniasis.